EUVIMEDEUVIMED entdecken
Fallbericht

Excellent RAI therapeutic response on a patient presenting skull metastasis of follicular thyroid cancer after 15 years

A Carbone, A Verrienti, D S Cito, C Corazza, R Bruno

Endocrine · 2024

DOI: 10.1007/s12020-024-04036-3 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Endocrine, 2024. Verfasst von A Carbone und 4 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine and Metabolic Diseases Unit, Local Health Authority, Matera, Italy. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Adenocarcinoma, Follicular, Iodine Radioisotopes, Skull Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bone is the second most common site of metastasis for differentiated thyroid carcinoma (DTC). Bone metastasis (BMs) occur in about 10% of patients with DTC and is observed more often in follicular thyroid carcinoma (FTC) (7-28%) than papillary thyroid carcinoma (PTC) (1-7%). Bone metastasis is associated with unfavorable clinical outcomes mainly including skeletal-related events (SREs), such as pathologic fractures, bone pain, spinal cord compressions, and hypercalcemia, which negatively impact the quality of life of patients and reduce their life expectancy. Patients with BMs from DTC require comprehensive and multimodal treatment approaches, including radioiodine (RAI) therapy, palliative care, surgery, external beam radiotherapy, and targeted drug therapy. RAI therapy is the first-line treatment, despite being rather ineffective, especially in large BMs. The response to RAI therapy, either alone or in combination with BM focal treatment depends on iodine avidity. This study reports a rare case of metachronous skull bone metastasis from FTC in a 72-year-old female patient 15 years after initial treatment. The patient had an excellent response to RAI therapy, which resulted in the abnormal uptake disappearing. Following treatment, the patient has been disease-free for six years. This case confirms that a complete response to RAI treatment for BM depends on the degree of dedifferentiation of cancer cells, which highlights the need for long-term follow-up, especially for FTC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsAdenocarcinoma, FollicularIodine RadioisotopesSkull NeoplasmsHumansFemaleAgedTreatment Outcome

Stichwörter der Autor:innen

Bone metastasesFollicular thyroid carcinomaRadioiodine

Substanzen

Iodine Radioisotopes

Autor:innen und Institutionen

  • Endocrine and Metabolic Diseases Unit, Local Health Authority, Matera, Italy.
  • Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
  • Endocrine and Metabolic Diseases Unit, Local Health Authority, Matera, Italy. roccobruno1@virgilio.it.

Zitieren

APA

Carbone, A., Verrienti, A., Cito, D. S., Corazza, C., & Bruno, R. (2024). Excellent RAI therapeutic response on a patient presenting skull metastasis of follicular thyroid cancer after 15 years. Endocrine. https://doi.org/10.1007/s12020-024-04036-3

Vancouver

Carbone A, Verrienti A, Cito DS, Corazza C, Bruno R. Excellent RAI therapeutic response on a patient presenting skull metastasis of follicular thyroid cancer after 15 years. Endocrine. 2024. doi:10.1007/s12020-024-04036-3

BibTeX
@article{Carbone2024,
  author = {Carbone, A and Verrienti, A and Cito, D S and Corazza, C and Bruno, R},
  title = {Excellent RAI therapeutic response on a patient presenting skull metastasis of follicular thyroid cancer after 15 years},
  journal = {Endocrine},
  year = {2024},
  doi = {10.1007/s12020-024-04036-3}
}
Kostenlos starten →